報價延遲最少15分鐘:2025/01/28 18:38 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.26/--
|
|
企業價值
6.62B
|
| 資產負債 |
|
每股賬面淨值
不適用
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/28 18:38 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company's geographical segments include the United States and Mainland China. |